An interventional study of oral CFG920 in patients with castration resistant prostate cancer

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-001961-33

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase I:To estimate the Maximum Tolerated Dose (MTD) or recommended phase II dose (RP2D) of oral CFG920 when co-administered with prednisone to adult patients with castration-resistant prostate cancer. Phase II: To assess preliminary anti-tumor activity of CFG920 across 3 castration-resistant prostate cancer groups:1) Abiraterone- naïve, 2) Abiraterone primary resistant, 3) Abiraterone secondary resistant


Critère d'inclusion

  • metastatic prostate cancer